Antimicrobial Agent Abbreviations
Amp- Ampicilin, Amox/Clav- Amoxicillin/Clavulanate, Amp/Sulb-Ampicillin/Sulbactam, Amik- Amikacin, Aztre-Aztreonam, Cefaz- Cefazolin, Ceftaz-Ceftazidime, Cefep-Cefepime, Chloro-Chloramphenicol, Clinda-Clindamycin, Eryth-Erythromycin, Gent-Gentamicin, Imip-Imipenem, Levo-Levofloxacin,Linz-Linezolid, Mero-Meropenem, Nitro-Nitrofurantoin, Norflox- Norfloxacin, Naf-Nafcillin, Pen-Penicillin, Pip/Tazo-Pipercillin/Tazobactam, Tetra-Tetracycline, Tmp/Sxt- Trimethoprim/Sulfamethoxazole, Tobra-Tobramycin, Vanco-Vancomycin
PMC Inpatients, Jan-Dec 2007, Blood Isolates
					Percent Susceptible
Organism	No	Amp or Pen	Amp/Sulb	Cefaz	Clinda	Eryth	Gent	Naf	Tmp/Sxt	Levo	Tetra	Linz	Vanco
S. aureus	93	3	48	48	46	24	95	48	99	53	98	100	100
Staphylococcus, coag neg	55	4	32	32	25**	25	65	32	nt	24	nt	100	100
Enterococcus sp	21	67	nt	nt	nt	14	85(70)*	nt	nt	43	nt	82	77
*hl- high level gentamicin, 500 ug/ml, high level streptomycin, 2000 ug/ml, in parenthesis
**CNS not routinely tested for inducible clinidamycin resistance,  susceptibily may be higher
					Percent Susceptible
Organism	No.	Amp	Amp/Sulb or Amox/Clav	Cefaz	Ceftaz	Cefep	Gent	Tobra	Amik	Levo	Pip (Pip/Tazo)	Tmp/Sxt	Mero
E. coli	61	59	69	98	98	98	92	90	100	74	82(98)	82	100
K. pneumoniae	26	0	58	81	81	81	96	81	81	77	0(85)	69	100
P. aeruginosa	20	nt	nt	nt	75	85	95	100	95	85	85	nt	85
PMC  Inpatients, Jan-Dec 2007, Non-Urinary Isolates
					Percent Susceptible
Organism	No	Amp or Pen	Amp/Sulb or Amox/Clav	Cefaz	Clinda	Ery	Gent	Naf	Tmp/Sxt	Levo	Tetra	Linz	Vanco
S. aureus	778	5	46	46	70	32	98	46	99	69	95	100	100
Staphylococcus, coag neg	47	8	36	36	28**	28	82	36	nt	49	nt	100	100
Enterococcus sp	110	72	nt	nt	nt	21	nt	nt	nt	57	39	93	81
*CNS not tested for inducible clindamycin resistance, susceptibility may be higher
Organism	No.	Amp	Amp/Sulb or Amox/Clav	Cefaz	Ceftaz	Cefep	Gent	Tobra	Amik	Levo	Mero	Pip (Pip/Tazo)	Tmp/Sxt
A. baumanii	21	0	91	0	40	57	67	67	76	52	nt	nt	62
Alcaligenes xylosoxidans	12	nt	nt	nt	36	0	0	0	0	23	82	100(100)	82
C. freundii	11	0	0	0	82	100	100	100	100	82	100	73 (nt)	100
E. cloacae	0	0	0	0	89	96	93	96	100	89	100	89(92)	96
E. coli	110	47	54	82	93	93	86	89	100	75	100	64(91)	78
K. pneumoniae	70	0	50	66	66	66	89	69	73	67	92	0(67)	67
K. oxytoca	14	0	93	86	100	100	100	100	100	100	100	0(93)	100
M. morganii	16	0	0	0	88	100	88	94	100	88	100	88(88)	69
P. mirabilis	42	83	93	91	95	95	93	95	100	83	100	93(97)	88
P. aeruginosa	197	nt	nt	nt	82	80	72	86	81	62	82	86 (nt)	nt
S. maltophila	29	nt	nt	nt	nt	nt	nt	nt	nt	nt	nt	nt	93
S, marcescens	25	0	0	0	100	100	100	100	100	92	100	96(100)	96
PMC Inpatients, Jan-Dec 2007, Urinary Isolates
					Percent Susceptible
Organism	No	Amp or Pen	Amp/Sulb or Amox/Clav	Cefaz	Ery	Clinda	Gent	Naf	Tmp/Sxt	Levo	Tetra	Linz	Vanco
S. aureus	77	5	57	57	42	52	100	57	99	53	88	100	100
Staphylococcus, coag neg	184	5	36	36	45	45**	89	36		57	nt	100	100
Enterococcus sp	397	85	nt	nt	18	nt	nt	nt	nt	69	27	96	86
**CNS not routinely tested for inducible clindamycin resistance, susceptibility may be higher
					Percent Susceptible
Organism	No.	Amp	Amp/Sulb or Amox/Clav	Cefaz	Ceftaz	Gent	Tobra	Levo	Norflox	Nitro	Pip (Pip/Tazo)	Tmp/Sxt	Tetra	Mero
C. koseri	45	0	100	100	100	98	100	100	100	89	nt	96	98	nt
C. freundii	21	0	0	0	76	91	95	95	95	100	nt	91	81	nt
Pantoea (Enterobacter) aerogenes	29	0	0	0	100	100	100	100	100	7	nt	100	100	nt
E. cloacae	39	0	0	0	82	92	90	82	82	26	nt	82	77	nt
E. coli	2129	61	84	92	99	94	95	85	85	97	nt	82	79	nt
K. pneumoniae	360	0	88	83	86	93	86	84	84	29	nt	82	85	nt
K. oxytoca	24	0	83	67	100	100	100	96	96	75	nt	96	100	nt
M. morganii	18	0	0	0	94	72	100	78	83	0	nt	61	61	nt
P. mirabilis	149	95	97	97	100	97	98	87	87	0	nt	87	0	nt
P. aeruginosa	96	nt	nt	nt	90	88	94	59	nt	nt	94	nt	nt	84